In contrast, OCI-AML2 NPM1mtA/wt cells exhibited increased levels of HOXA9, MEIS1, and c-Myc, and notably these cells were sensitized in vitro and in vivo to MI-induced anti-AML efficacy. The gene discussed is MYC; the disease is acute myeloid leukemia.